Curated from medtech publications. Product launches, FDA clearances, M&A, technology shifts — rewritten as short briefs, linked back to the source. Filter by theme below.
Teleflex received FDA breakthrough device designation for its Freesolve RMS coronary scaffold, intended for percutaneous coronary intervention (PCI). Breakthrough status expedites FDA review and signals potential clinical significance for the device.
Medtronic released real-world evidence from its registry supporting the performance of its cardiac ablation systems in patients with atrial fibrillation and ventricular tachycardia. The findings reflect clinical outcomes from deployed ablation platforms and contribute to the vendor's clinical validation portfolio for rhythm-management technologies.
Alcon acquired Neurotech Pharmaceuticals for $550 million, adding the rare vision disorder cell therapy Encelto and its underlying platform technology to its portfolio. The deal follows Alcon's majority stake investment in Aurion Biotech last year, which is developing a corneal cell therapy. The acquisitions signal Alcon's strategic pivot toward cell therapy as a growth area within ophthalmology.
EQT Partners agreed to acquire Qiagen, a diagnostics equipment and consumables manufacturer, for €9.6 billion. The transaction marks a significant consolidation in the in vitro diagnostics sector and follows sustained private-equity interest in the company.
Lunit presented results from multiple SCOPE studies at ESMO26 demonstrating the clinical application of its AI-based pathology software across various cancer types. SCOPE is an artificial-intelligence platform designed to assist pathologists in diagnostic analysis. The studies highlight the technology's performance across diverse oncology applications, signaling vendor investment in AI-driven diagnostic tools for the pathology workflow.
St Luke's Health System has selected hellocare.ai to deploy an AI-assisted virtual care platform across its inpatient facilities in Idaho. The implementation represents a vendor adoption of digital health software for patient engagement and care delivery across multiple hospital sites.
The UK government has confirmed indefinite recognition of EU CE marks for medical devices, reversing earlier post-Brexit plans that would have required separate UK certification by 2030. The decision allows CE-marked medical technology to circulate in the UK market without additional regulatory approval, simplifying compliance for suppliers operating across both markets.
Edwards Lifesciences has secured FDA approval for PASCAL Precision, a tricuspid valve repair system. The approval marks clearance of the minimally invasive device for treatment of tricuspid regurgitation in eligible patients.
Intuitive Surgical revised its 2026 procedural growth guidance downward to a 14–15% midpoint, from a prior range of 13.5–15.5%, triggering an 8% decline in share price. The adjustment signals softer near-term demand expectations for the robotic surgery platform amid broader market conditions.
The American Medical Association submitted comments on the FDA's proposed regulatory framework for generative AI-based medical devices, urging the agency to prioritize safety over speed in approval processes and calling for physician input on clinical performance standards and evaluation criteria for AI-driven medtech.
Maxon UK & Ireland's medical business unit head explains the role of force feedback and coreless brushless DC motors in robotic surgical systems. Force feedback enables surgeons to sense tissue resistance and optimize instrument control during minimally invasive procedures, while coreless motor designs improve precision and reduce size constraints in surgical robotics.
IceCure Medical has enrolled the first two patients at two US clinical centers in the ChoICE trial evaluating its ProSense cryoablation system for treatment of low-risk breast cancer. The trial marks an early-stage clinical assessment of the company's ablation device in a breast-cancer indication.
Abbott obtained CE Mark approval under the EU's In Vitro Diagnostic Regulation (IVDR) for Cologuard Plus, a colorectal cancer screening test. The regulatory clearance permits the company to market the diagnostic across European Union member states.
Rick Abramson, director of the FDA's Digital Health Center of Excellence and a radiologist, stated that generative AI-enabled medical tools may require regulatory assessment frameworks distinct from traditional devices. Abramson suggested these tools behave more like physician decision-support systems than conventional hardware, implying the FDA may need to adapt its approval and oversight approach for AI-driven diagnostics and clinical software.
Medtronic's Vitalis pacemaker portfolio has secured CE mark approval in Europe. The five-device portfolio uses conduction system pacing technology to stimulate the heart's native electrical pathways, enabling physicians to deliver therapy closer to the heart's natural conduction system.
Formacoat has introduced HydroMark™, a hydrophilic coating technology for medical devices. The coating is designed to give device manufacturers greater choice, flexibility, and supply-chain resilience in their manufacturing processes.
The WHO granted an emergency use listing (EUL) to bioMérieux's BioFire Ebola panel for detection of Bundibugyo virus, making it the fifth diagnostic to receive such authorization since the outbreak was declared a public health emergency in May 2026. The listing enables rapid deployment of the multiplexed PCR assay in affected Central African regions.
Phantom GI, a Tel Aviv-based startup, secured $5 million in funding to develop PercStoma, a minimally invasive device designed as an alternative to traditional ostomy surgery for patients with bowel obstructions. The device targets patients who may be ineligible for conventional surgical approaches.
Masimo received FDA clearance for atrial fibrillation detection via its Radius VSM vital signs monitor using photoplethysmography (PPG) technology. The clearance expands the platform's capabilities following a June 2026 clearance for opioid-induced respiratory depression detection on the same device.
The FDA has cleared Sequel Med Tech's twiist AID system for adults aged 18 and older with insulin-treated type 2 diabetes. The clearance expands the automated insulin delivery platform's authorized use from type 1 diabetes, marking a significant regulatory milestone for the vendor's diabetes management portfolio.
Sirona Medical closed a $40 million Series D funding round led by Avidity Partners to scale its cloud-based radiology platform. The company said the capital will extend its operating runway indefinitely as it expands its software offering for radiology workflows.
Medical technology companies are adopting AI-driven approaches to integrate data across disparate systems while maintaining regulatory compliance. The shift toward a connected, agent-ready enterprise model enables vendors to leverage intelligence for operational efficiency without compromising patient data security or adherence to healthcare regulations. This architecture allows MedTech suppliers to standardize data workflows and improve interoperability across their product ecosystems.
Edwards Lifesciences' SAPIEN M3 transcatheter mitral valve replacement system delivery component has been linked to one patient death and one serious injury, according to an FDA alert issued as of October 5. The specific failure mode and scope of affected devices were not detailed in the available information.
Vivos Therapeutics has agreed to acquire an 11% fully diluted equity stake in SOD Sciences and a 50% co-ownership interest in SOD Sciences' pseudohypoxia early-warning diagnostic test. The investment represents a partnership to develop and commercialize the diagnostic technology.
GE HealthCare obtained CE Mark certification for its MINItrace Magni cyclotron and expanded its PETtrace Solid Target Platform to support Copper-64 production. The cyclotron is used in radiopharmaceutical manufacturing for positron emission tomography imaging.
Sourabh Pagaria, president of ultrasound at Siemens Healthineers, discusses advances in cardiac imaging workflows and the role of technology in supporting modern cardiac procedures. The discussion emphasizes workflow optimization alongside innovation in imaging platforms.
Labcorp agreed to acquire BioReference's laboratory assets for up to $872 million. The transaction is intended to expand Labcorp's laboratory service capacity and accessibility. BioReference operates a network of clinical laboratory facilities serving patients and providers across multiple regions.
The FDA issued a warning letter to Olympus following inspections at six of the company's international manufacturing sites completed in late 2025, citing manufacturing failures. The warning triggered a sharp decline in Olympus' share price, signaling regulatory enforcement action against a major medical device supplier.
Centinel Spine received FDA approval to expand ProDisc C Nova, its cervical total disc replacement system, for two-level use. The expansion permits the device to treat degenerative disc disease across two adjacent vertebral levels in the cervical spine, broadening its clinical application from prior single-level clearance.
Stryker received FDA 510(k) clearance for Sonopet 3, an ultrasonic surgical platform designed for bone and soft tissue removal. The device represents an update to the company's existing Sonopet line of ultrasonic instruments used in orthopedic and general surgical procedures.
Healthleap, a clinical AI platform integrated with electronic health records to screen hospitalized patients for undiagnosed conditions, raised $38 million in funding. The capital will support expansion of the platform's ability to identify at-risk patients earlier in hospital care. Healthleap operates within existing EHR systems to flag potential missed diagnoses.
Hospitals are deploying agentic AI systems to automate clinical and administrative processes and reduce staff burden, but face challenges with pilot sprawl as simultaneous deployments proliferate beyond organizational tracking capacity. The article examines how hospitals can effectively implement and manage AI agents by maintaining focused, controlled rollouts rather than attempting broad concurrent pilots.
Agilent Technologies has agreed to acquire Proscia for up to $270 million, with closing expected in fiscal 2027. The deal follows Agilent's $950 million purchase of Biocare Medical in March 2026, continuing the company's expansion in pathology and digital diagnostics.
The FDA granted 510(k) clearance to Providence Medical Technology for the CORUS Posterior Cervical Stabilization System 3D-T, a spinal fixation device designed for posterior cervical spine surgery. The clearance permits market distribution of the system for stabilization of the cervical spine in indicated patient populations.
Butterfly Medical obtained EU MDR (Medical Device Regulation) certification for its Butterfly Prostatic Retraction Device, a benign prostatic hyperplasia implant. The certification clears the device for commercial distribution across European Union member states.
Happy Health received FDA clearance for a wearable ring that continuously measures blood pressure without a cuff or external calibration. The device represents a new form factor for non-invasive blood pressure monitoring, eliminating the need for traditional cuff-based measurement.
Abram secured an $8.3 million US Department of Defense contract to advance its blood coagulation diagnostic technology. The award follows the company's $10.75 million financing round completed in February and supports progress toward an FDA filing for the diagnostic device.
A Morgan Lewis partner discusses the FDA's recently released discussion paper on regulating generative AI in medical technology. The conversation covers the agency's proposed framework for oversight of GenAI-based devices, including potential pathways for clearance and post-market monitoring, as the FDA shapes regulatory strategy around AI-driven medical tools.
The FDA has issued a discussion paper proposing a regulatory framework for generative AI in medical devices, with stakeholder feedback open until October 19, 2026. The proposal addresses oversight of GenAI-based medtech products, including questions around pre-market review, post-market monitoring, and software change management. Suppliers and device makers are invited to submit comments on the agency's evolving approach to AI regulation.
Steris has acquired Xodus Medical for $2.1 billion, adding the company's surgical safety device portfolio—including the Pink Pad—to Steris' existing lineup. The deal expands Steris' offerings in the operating room safety segment.
749 older stories available.